Cognition Therapeutics Inc
cogrx.comWhat Do They Do?
Develops small-molecule drug candidates for age-related diseases of the brain and retina, including Alzheimer’s disease and dementia with Lewy bodies.
10-K for FY2025, filed Mar 26, 2026
Sources
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 26, 2026
Sources
How Are They Changing?
Since the FY2025 annual report
Latest quarter: Q2 FY2026, the three months to Jun 30, 2026
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 7, 2026
−$3.9MView ↗
- ▼ −42% (Loss)
- vs −$6.7M in Q2 FY2025
-
Aug 6, 2026
FDA discussions clarified plans for a DLB psychosis Phase 3 trial
The company plans to initiate the study in mid-2027 and reported a new patent application allowance.
Sources
8-K, filed Aug 6, 2026
“The second quarter marked important progress across both our clinical and corporate priorities,” said Lisa Ricciardi, Cognition’s…View ↗
-
Jun 24, 2026
FDA aligned with key aspects of a pivotal DLB psychosis trial
The company expects the registrational program to begin in mid-2027.
Sources
8-K, filed Jun 24, 2026
PURCHASE, NY – June 24, 2026 – Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company…View ↗
Loading...
Comments
